Clinical feasibility was investigated by analyzing whole blood specimens from non-small cell lung cancer (NSCLC) patients and cholangiocarcinoma patient, using the epithelial marker EPCAM and the epithelial–mesenchymal transition (EMT) biomarkers vimentin and MET. This evidence concerns the gene VIM and non-small cell lung carcinoma.